Debutyldronedarone-d7 (hydrochloride)

• UNSPSC Description:

  Debutyldronedarone-d7 hydrochloride is deuterated labeled Debutyldronedarone hydrochloride (HY-12753A). Debutyldronedarone (SR35021) hydrochloride, the main metabolite of Dronedarone, is a selective thyroid hormone receptor α1 (TRα1) inhibitor. Debutyldronedarone hydrochloride inhibits T3 binding to TRα1 and TRβ1 by 77% and 25%, respectively. Debutyldronedarone hydrochloride can be used for the research of arrhythmic[1].

• Target Antigen:

  Isotope-Labeled Compounds; Thyroid Hormone Receptor

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Others;Vitamin D Related/Nuclear Receptor

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Solubility:

  10 mM in DMSO

• Smiles:

  [2H]C([2H])(C([2H])(CNCCCOC1=CC=C(C=C1)C(C2=C(OC3=C2C=C(C=C3)NS(C)(=O)=O)CCCC)=O)[2H])C([2H])([2H])[2H].Cl

• Molecular Weight:

  544.15

• References & Citations:

  [1]Van Beeren HC, et al. Dronerarone acts as a selective inhibitor of 3,5,3'-triiodothyronine binding to thyroid hormone receptor-alpha1: in vitro and in vivo evidence. Endocrinology. 2003 Feb;144(2):552-8.|[2]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported